MANKIND

Mankind Pharma Share Price

₹2,385.80 -79.5 (-3.22%)

03 May, 2025 03:52

SIP TrendupStart SIP in MANKIND

Start SIP

Performance

  • Low
  • ₹2,359
  • High
  • ₹2,468
  • 52 Week Low
  • ₹1,901
  • 52 Week High
  • ₹3,055
  • Open Price₹2,467
  • Previous Close₹2,465
  • Volume380,164

Investment Returns

  • Over 1 Month -2.94%
  • Over 3 Month -3.86%
  • Over 6 Month -11%
  • Over 1 Year + 0.91%
SIP Lightning

Smart Investing Starts Here Start SIP with Mankind Pharma for Steady Growth!

Invest Now

Mankind Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 48.2
  • PEG Ratio
  • 2.7
  • Market Cap Cr
  • 98,433
  • P/B Ratio
  • 9.3
  • Average True Range
  • 92.38
  • EPS
  • 49.48
  • Dividend Yield
  • 0
  • MACD Signal
  • 45.36
  • RSI
  • 43.55
  • MFI
  • 46.88

Mankind Pharma Financials

Mankind Pharma Technicals

EMA & SMA

Current Price
₹2,385.80
-79.5 (-3.22%)
pointer
  • stock-down_img
  • Bearish Moving Average 15
  • stock-up_img
  • Bullish Moving Average 1
  • 20 Day
  • ₹2,474.06
  • 50 Day
  • ₹2,446.61
  • 100 Day
  • ₹2,465.87
  • 200 Day
  • ₹2,429.08

Resistance and Support

2404.17 Pivot Speed
  • R3 2,558.93
  • R2 2,513.47
  • R1 2,449.63
  • S1 2,340.33
  • S2 2,294.87
  • S3 2,231.03

What's your outlook on Mankind Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Mankind Pharma Ltd. is one of India’s largest pharmaceutical companies, providing a wide range of affordable medicines in areas like antibiotics, cardiovascular, gastrointestinal, and dermatology. It also manufactures over-the-counter (OTC) products, catering to domestic and global markets.

Mankind Pharma Ltd has an operating revenue of Rs. 11,641.03 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 23% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its key moving averages, around 3% and -0% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 19% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 63 which is a FAIR score but needs to improve its earnings, a RS Rating of 73 which is FAIR indicating the recent price performance, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 76 indicates it belongs to a poor industry group of Medical-Products and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Mankind Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-01-23 Quarterly Results
2024-11-05 Quarterly Results
2024-07-31 Quarterly Results
2024-05-15 Audited Results & Others To evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals.
2024-01-31 Quarterly Results

Mankind Pharma F&O

Mankind Pharma Shareholding Pattern

72.7%
7.67%
2.23%
12.92%
1.64%
2.84%

About Mankind Pharma

  • NSE Symbol
  • MANKIND
  • BSE Symbol
  • 543904
  • ISIN
  • INE634S01028

Similar Stocks to Mankind Pharma

Mankind Pharma FAQs

Mankind Pharma share price is ₹2,385 As on 03 May, 2025 | 03:39

The Market Cap of Mankind Pharma is ₹98433 Cr As on 03 May, 2025 | 03:39

The P/E ratio of Mankind Pharma is 48.2 As on 03 May, 2025 | 03:39

The PB ratio of Mankind Pharma is 9.3 As on 03 May, 2025 | 03:39

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23